Search
Menu
Home
Sources
About
Contacts
Dipraglurant
Dipraglurant
is a
negative allosteric modulator
of the mGlu
5
receptor
which is
under development
by
Addex Therapeutics
for the
treatment of Parkinson's disease
levodopa-induced dyskinesia
. As of
2014
, it is
in phase
II
clinical trials
for this
indication
. Addex
Therapeutics
is also
investigating
an
extended-release formulation
of dipraglurant for the
treatment
of non-parkinsonian
dystonia
.